Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herba Asimor is an Indonesian Modern Medicine (OMAI) developed by Dexa Medica Group's Dexa Laboratories of Biomolecular Sciences (DLBS) to address insufficient milk supply in postpartum lactating mothers. It is a combination product featuring Galatonol—a bioactive fraction derived from *Sauropus androgynus* (katuk) and *Coleus amboinicus* (torbangun) leaves—and Striatin, a bioactive fraction from *Channa striata* (snakehead fish). The product is manufactured using Advanced Fractionation Technology (AFT) to ensure high purity and biological activity. Mechanistically, Herba Asimor works by upregulating the expression of genes for prolactin and oxytocin, the key hormones involved in milk synthesis and the let-down reflex. Clinical studies and consumer reports indicate significant increases in breast milk volume within days of starting supplementation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Herba Asimor.